Condition
Recurrent Glioblastoma IDH Wildtype
Total Trials
5
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Early P 1 (3)
P 1 (2)
Trial Status
Recruiting4
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07712770Early Phase 1Not Yet RecruitingPrimary
Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma
NCT07655869Early Phase 1Recruiting
[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
NCT07648823Early Phase 1Recruiting
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
NCT07318818Phase 1RecruitingPrimary
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
NCT06455605Phase 1RecruitingPrimary
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
Showing all 5 trials